Abstract
IntroductionThis study evaluated acute change in odor identification following atropine nasal spray challenge, and 8‐week change in odor identification ability, as a predictor of long‐term improvement in patients with mild to moderate Alzheimer's disease (AD) who received open‐label cholinesterase inhibitor treatment.MethodsIn patients with clinical AD, the University of Pennsylvania Smell identification Test (UPSIT) was administered before and after an anticholinergic atropine nasal spray challenge. Patients were then treated with donepezil for 52 weeks.ResultsIn 21 study participants, acute atropine‐induced decrease in UPSIT was not associated with change in the Alzheimer's Disease Assessment Scale ‐ Cognitive Subscale (ADAS‐Cog) or Selective Reminding Test (SRT). Decline in odor identification performance from baseline to week 8 was indicative of a future decline in cognitive performance over 52 weeks.DiscussionChange in odor identification with atropine challenge is not a useful predictor of treatment response to cholinesterase inhibitors. Short‐term change in odor identification performance needs further investigation as a potential predictor of cognitive improvement with cholinesterase inhibitor treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.